Biocept

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that...

In illiquid pre-market trading, Biocept Inc (NASDAQ: BIOC) was indicated 6 percent higher at $2.08 following a bullish note from H.C. Wainwright & Co. analyst Yi Chen. Chen, who has a Ph.D. in biochemistry, is optimistic on Biocept's liquid biopsy technology, which he said provides...